There is evidence that targeting CDKs in addition to conventional platinum medications may significantly improve the effectiveness of treatments for ovarian cancer (Zhou, 2017); CDK4 and CDK6 inhibitors may be effective in oral squamous cell carcinoma (Kujan et al., 2019); CDK inhibition has the potential to treat pancreatic ductal adenocarcinoma (Garcia-Reyes et al., 2018); breast cancer, including triple-negative and advanced breast cancer, is common cancer for which CKIs are used (Sarosiek, 2018; Quereda et al., 2019; Sofi et al., 2022). The gene discussed is CDK6; the disease is cancer.